Kurv Yield Prem Strategy Tesla ETF (TSLP)
| Assets | $19.90M |
| Expense Ratio | 1.00% |
| PE Ratio | 120.49 |
| Shares Out | 1.03M |
| Dividend (ttm) | $8.46 |
| Dividend Yield | 43.85% |
| Ex-Dividend Date | May 7, 2025 |
| Payout Ratio | 5,283.89% |
| 1-Year Return | -4.16% |
| Volume | 48,883 |
| Open | 18.96 |
| Previous Close | 18.88 |
| Day's Range | 18.96 - 19.51 |
| 52-Week Low | 15.36 |
| 52-Week High | 34.29 |
| Beta | n/a |
| Holdings | 11 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Top 10 Holdings
122.57% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B 0 06.26.25 | 33.88% |
| United States Treasury Bills 0% | B 0 09.18.25 | 31.79% |
| United States Treasury Bills 0% | B 0 05.15.25 | 29.69% |
| TSLA US 06/20/25 C280 | n/a | 21.08% |
| Fidelity Government Portfolio | FIGXX | 4.76% |
| Cash Offset | n/a | 2.81% |
| DEPOSITS WITH BROKER FOR SHORT POSITIONS | n/a | 2.48% |
| TSLA US 08/15/25 P210 | n/a | 0.42% |
| TSLA US 07/18/25 P175 | n/a | 0.29% |
| TSLA US 06/20/25 C345 | n/a | -4.63% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| May 7, 2025 | $0.550 | May 8, 2025 |
| Apr 2, 2025 | $0.550 | Apr 3, 2025 |
| Mar 5, 2025 | $0.700 | Mar 6, 2025 |
| Feb 5, 2025 | $1.000 | Feb 6, 2025 |
| Jan 23, 2025 | $1.300 | Jan 24, 2025 |
| Dec 24, 2024 | $1.30003 | Dec 26, 2024 |
News
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...